文献速递浆细胞疾病

转录因子EB及其靶基因在硼替佐米治疗多发性骨髓瘤中的作用与分子机制

[The role and molecular mechanism of transcription factor EB and its target genes in multiple myeloma treatment with bortezomib].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2025-01-01

该研究探讨TFEB及其靶基因Ptch1在硼替佐米治疗多发性骨髓瘤(MM)中的作用。体外实验显示硼替佐米降低MM细胞系Ptch1表达,敲低TFEB可逆转硼替佐米对Ptch1/Hedgehog通路的抑制;过表达Ptch1则减少硼替佐米诱导的自噬并逆转其对MM细胞系的增殖抑制。

要点

  • 硼替佐米处理MM细胞系后Ptch1 mRNA和蛋白水平较空白对照降低。
  • 敲低TFEB逆转硼替佐米对Hedgehog通路关键因子Ptch1和Gli的抑制。
  • 过表达Ptch1减少硼替佐米处理MM细胞的自噬相关蛋白和溶酶体数量。

核心结论

  • 敲低TFEB可靶向促进Ptch1/Hedgehog信号通路表达而减少硼替佐米诱导的MM细胞自噬,并逆转硼替佐米对MM细胞系的增殖抑制作用。

研究设计与样本

  • 体外研究,使用MM细胞系RPMI8226和U266,通过GTRD数据库预测TFEB靶基因并筛选Ptch1。
  • 采用RT-qPCR和Western blot检测基因表达,siRNA-TFEB转染敲低TFEB,慢病毒转染过表达Ptch1。
  • 自噬评估采用吖啶橙染色,溶酶体数量采用溶酶体荧光探针,蛋白水平采用Western blot检测LC3B、Beclin-1、Lamp-1。

主要发现

  • 硼替佐米(6.0×10(-6) mmol/L,24 h)处理RPMI8226和U266细胞系后,Ptch1 mRNA和蛋白相对表达水平均较空白对照组降低(P值均<0.05)。
  • 转染siRNA-TFEB后逆转了硼替佐米对Hedgehog通路中关键因子Ptch1、Gli的抑制作用。
  • Ptch1过表达显著减少经硼替佐米处理的RPMI8226和U266细胞系中自噬相关因子LC3B、Beclin1、Lamp1蛋白相对表达量(P值均为0.001)。
  • 吖啶橙染色显示两种细胞系酸性囊泡数量均减少(P值均为0.001)。
  • 反映溶酶体数量的溶酶体探针相对荧光表达亦减少(RPMI8226和U266细胞系的P值分别为0.001、0.007)。

临床怎么用

  • 提示TFEB-Ptch1/Hedgehog轴可能参与硼替佐米诱导的MM细胞自噬调控,为联合靶向自噬增敏硼替佐米提供体外依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the role and molecular mechanisms of transcription factor EB (TFEB) and its target genes in the treatment of multiple myeloma (MM) with bortezomib. Methods: TFEB target genes were predicted using the GTRD database (http://gtrd.biouml.org/), identifying Ptch1 gene for further study. Expression changes of Ptch1 in RPMI8226 and U266 MM cell lines after bortezomib treatment were assessed by real time fluorogenic quantitative PCR (RT-qPCR) and Western blot. RPMI8226 and U266 cell lines were transfected with siRNA-TFEB, and mRNA and protein levels of key factors (Ptch1, Gli1) in the Ptch1/Hedgehog signaling pathway were measured by RT-qPCR and Western blot. Furthermore, Ptch1 was overexpressed in MM cell lines via lentiviral transduction. Autophagy was evaluated by acridine orange staining, and protein levels of LC3B, Beclin-1, and Lamp-1 were measured by Western blot. Lysosomal quantity changes were assessed by lysosomal fluorescent probes. Results: Bortezomib (6.0×10(-6) mmol/L, 24 h) significantly reduced Ptch1 mRNA and protein levels in both cell lines compared with blank control group (all P<0.05). siRNA-TFEB transfection reversed bortezomib's inhibition of Hedgehog pathway key factors Ptch1 and Gli. Ptch1 overexpression in bortezomib-treated RPMI8226 and U266 cells significantly reduced the relative expression of autophagy-related proteins LC3B, Beclin-1, and Lamp-1 (all P=0.001). Acridine orange staining showed fewer acidic vesicular organelles within two cell lines (all P=0.001). The relative fluorescence expressions of lysosomal probes reflecting the number of lysosomes were also decreased (P values of RPMI8226 and U266 cell lines were 0.001 and 0.007, respectively) . Conclusion: The knockdown of TFEB can specifically promote the expression of the Ptch1/Hedgehog signaling pathway, thereby reducing bortezomib-induced autophagy in MM cells and reversing the inhibitory effect of bortezomib on the proliferation of MM cell lines. 目的: 探索转录因子EB(TFEB)及其靶基因在硼替佐米治疗多发性骨髓瘤(MM)中的作用及分子机制。 方法: 通过GTRD网站(http://gtrd.biouml.org/)预测TFEB靶基因,筛选出Ptch1基因。实时荧光定量PCR和Western blot法检测硼替佐米作用于MM细胞系RPMI8226和U266后Ptch1的表达变化。siRNA-TFEB分别转染RPMI8226和U266细胞系,实时荧光定量PCR和Western blot法检测Ptch1/Hedgehog信号通路关键因子(Ptch1、Gli1)的mRNA和蛋白相对表达情况。在MM细胞系中用慢病毒转染过表达Ptch1,吖啶橙染色观察自噬现象,Western blot法检测各组细胞自噬相关因子(LC3B、Beclin-1、Lamp-1)蛋白相对表达量,溶酶体荧光探针观察溶酶体数量变化。 结果: 硼替佐米(6.0×10(-6) mmol/L)处理RPMI8226和U266细胞系24 h,硼替佐米组Ptch1的mRNA和蛋白的相对表达水平均较空白对照组降低(P值均<0.05),转染siRNA-TFEB后逆转了硼替佐米对Hedgehog通路中关键因子Ptch1、Gli的抑制作用。Ptch1过表达显著减少了经硼替佐米处理的RPMI8226和U266细胞系中自噬相关因子LC3B、Beclin1、Lamp1蛋白的相对表达量(P值均为0.001)。吖啶橙染色显示两种细胞系酸性囊泡数量均减少(P值均为0.001),反映溶酶体数量的溶酶体探针相对荧光表达亦减少(RPMI8226和U266细胞系的P值分别为0.001、0.007)。 结论: 敲低TFEB可靶向促进Ptch1/Hedgehog信号通路表达而减少硼替佐米诱导的MM细胞自噬,并逆转硼替佐米对MM细胞系的增殖抑制作用。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang RJ, Wang ZL, Shi XM, et al. [The role and molecular mechanism of transcription factor EB and its target genes in multiple myeloma treatment with bortezomib]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 41407464. doi:10.3760/cma.j.cn121090-20250614-00276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。